Analysis of NINDS Health Disparities and Health Equity Research Portfolio, 2016-2020: Results and a Process for Transparency, Accuracy, and Reliability.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
15 08 2023
Historique:
received: 08 09 2022
accepted: 09 05 2023
pmc-release: 15 08 2024
medline: 16 8 2023
pubmed: 15 8 2023
entrez: 14 8 2023
Statut: ppublish

Résumé

As detailed throughout this special issue, the National Institute of Neurological Disorders and Stroke (NINDS) recently undertook a strategic planning effort to guide the Institute's efforts and priorities in health disparities and health equity (HD/HE) research. One input into this effort was to conduct a 5-year longitudinal, in-depth analysis of NINDS-supported HD/HE research newly funded between the years 2016 and 2020. The goals of this analysis were to describe NINDS's portfolio according to consistent, contemporary definitions and HD/HE disciplinary theory. This required the development of a novel, systematic, and validated analysis protocol. The portfolio analysis was designed to inform the recommendations of an expert working group convened by the NINDS and internal efforts to support high-priority research, training, and infrastructure efforts. NINDS staff developed and validated this HD/HE research portfolio analysis protocol. Ultimately, HD/HE projects were characterized by their disease focus, populations of study, the health equity determinant(s) addressed, and the type and phase of research being conducted. For all interventional research, there was further assessment of the type and setting of intervention delivery as well as utilization of evidence-based community engagement and intervention sustainability approaches. A total of 58 new HD/HE research projects were funded from 2016 to 2020. The results of the descriptive analysis described here help provide a holistic picture of NINDS's HD/HE research portfolio, revealing strengths and gaps in the portfolio as well as opportunities ripe for future investment. NINDS developed a standardized HD/HE research categorization methodology with imbedded quality control checks that is intended to be transparent, accurate, and reproducible. The results of this HD/HE research portfolio analysis will serve as a baseline from which to assess the success of NINDS's research investments going forward.

Sections du résumé

BACKGROUND AND OBJECTIVES
As detailed throughout this special issue, the National Institute of Neurological Disorders and Stroke (NINDS) recently undertook a strategic planning effort to guide the Institute's efforts and priorities in health disparities and health equity (HD/HE) research. One input into this effort was to conduct a 5-year longitudinal, in-depth analysis of NINDS-supported HD/HE research newly funded between the years 2016 and 2020. The goals of this analysis were to describe NINDS's portfolio according to consistent, contemporary definitions and HD/HE disciplinary theory. This required the development of a novel, systematic, and validated analysis protocol. The portfolio analysis was designed to inform the recommendations of an expert working group convened by the NINDS and internal efforts to support high-priority research, training, and infrastructure efforts.
METHODS
NINDS staff developed and validated this HD/HE research portfolio analysis protocol. Ultimately, HD/HE projects were characterized by their disease focus, populations of study, the health equity determinant(s) addressed, and the type and phase of research being conducted. For all interventional research, there was further assessment of the type and setting of intervention delivery as well as utilization of evidence-based community engagement and intervention sustainability approaches.
RESULTS
A total of 58 new HD/HE research projects were funded from 2016 to 2020. The results of the descriptive analysis described here help provide a holistic picture of NINDS's HD/HE research portfolio, revealing strengths and gaps in the portfolio as well as opportunities ripe for future investment.
DISCUSSION
NINDS developed a standardized HD/HE research categorization methodology with imbedded quality control checks that is intended to be transparent, accurate, and reproducible. The results of this HD/HE research portfolio analysis will serve as a baseline from which to assess the success of NINDS's research investments going forward.

Identifiants

pubmed: 37580151
pii: 101/7_Supplement_1/S82
doi: 10.1212/WNL.0000000000207569
pmc: PMC10605950
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S82-S91

Informations de copyright

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Auteurs

Sara Dodson (S)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

Shardell Spriggs (S)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

Ryan Calabrese (R)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

Stacey Chambers (S)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

Marguerite Matthews (M)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

Cheryse Sankar (C)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

Alisa Schaefer (A)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

Christine Swanson-Fischer (C)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

Devon Crawford (D)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

George Umanah (G)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD.

Richard T Benson (RT)

From the National Institute of Neurological Diseases and Stroke (S.D., R.C.), Office of the Director, and National Institute of Neurological Diseases and Stroke (S.S., S.C., M.M., C.S., A.S., C.S.-F., D.C., G.U., R.T.B.), Office of Extramural Research, NIH, Bethesda, MD. richard.benson@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH